Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05568212 2025-12-01

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Phase 2 Recruiting

176 enrolled

Thoracic

Non-small-cell Lung Cancer Patients

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06130254 2025-10-14

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Recruiting

52 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

870 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

220 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Completed

45 enrolled 30 charts

GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT04624204 2025-07-02

MK 7339-013

Phase 3 Active not recruiting

672 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05623319 2025-06-24

THOR

Phase 2 Recruiting

60 enrolled

Thoracic

SCLC,Extensive Stage

NCT06419179 2025-05-20

GUIDANCE

Phase 2 Enrolling by invitation

29 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04515836 2025-05-06

Olaparib in Patients With HRD Malignant Mesothelioma

Phase 2 Recruiting

56 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma

NCT03532880 2025-02-07

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Phase 1 Completed

26 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase 2 Terminated

4 enrolled 11 charts

EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2 Completed

72 enrolled 29 charts

Thoracic

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT06217757 2024-05-13

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

45 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

999 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT04375267 2023-11-14

LuPARP

Phase 1 Unknown

18 enrolled

EndocrineNETOther solid neoplasmThoracic

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT05411679 2023-06-12

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Phase 2 Withdrawn

GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Phase 2 Unknown

60 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02446704 2022-02-07

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Phase 1/2 Unknown

66 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03531840 2021-04-09

Olaparib in People With Malignant Mesothelioma

Phase 2 Completed

23 enrolled 16 charts

Other solid neoplasmThoracic

Mesothelioma

NCT03009682 2021-02-18

SUKSES-B

Phase 2 Completed

15 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03428607 2021-02-18

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

Phase 2 Completed

26 enrolled

Thoracic

SCLC

NCT02511795 2019-11-07

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Phase 1 Completed

128 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT01788332 2018-10-26

PIN

Phase 2 Unknown

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02679963 2017-08-01

PIPSeN

Phase 2 Unknown

600 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

QLS5132 Combination Therapy in Advanced Solid Tumors

MEDIOLA

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

CONCORDE

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

HUDSON

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

MK-7339-012

Study to Evaluate CCS1477 in Advanced Tumours

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

MK 7339-013

THOR

GUIDANCE

Olaparib in Patients With HRD Malignant Mesothelioma

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

GOAL

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

SAFIR02_Lung

LuPARP

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Olaparib in People With Malignant Mesothelioma

SUKSES-B

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

PIN

PIPSeN